A systematic review and meta-analysis evaluates the efficacy and safety of CSF1R inhibitors for treating recurrent or unresectable tenosynovial giant cell tumor. The findings from phase III randomized controlled trials provide insights into potential treatment options for this rare tumor.
efficacy and safety of csf1r inhibitors for recurrent or unresectable tenosynovial giant cell tumor a systematic review and meta analysis of phase iii randomized controlled trials
Original title: “Efficacy and Safety of CSF1R Inhibitors for Recurrent or Unresectable Tenosynovial Giant Cell Tumor: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.”